Top

Published in:

01-10-2015 | Research Paper

Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice

Authors: Jae-Hwi Jang, Lesley Baerts, Yannick Waumans, Ingrid De Meester, Yoshito Yamada, Perparim Limani, Ignacio Gil-Bazo, Walter Weder, Wolfgang Jungraithmayr

Published in: Clinical & Experimental Metastasis | Issue 7/2015

Abstract

Metastases rather than primary cancers determine nowadays the survival of patients. One of the most common primary malignancies is colorectal cancer and this type of tumor is characterized by a high tendency to spread metastases to the lung and liver. CD26/DPP4 is a transmembrane molecule with enzymatic functions which cleaves biologically active peptides. Recently, CD26/DPP4 has become the focus of cancer research and it was shown that CD26/DPP4-positive cancer cells display increased metastatic activity. Here, we tested if the CD26/DPP4-inhibitor Vildagliptin suppresses the development and growth of mouse colorectal lung metastases. This inhibitor of CD26/DPP4 was employed on mouse (C57BL/6) colorectal lung metastases, established by intravenous injection of the syngeneic cell line MC38. For mechanistic analysis, a subcutaneous tumor model was used. The treatment with Vildagliptin significantly suppressed both, the incidence and growth of lung metastases. Autophagy markers (LC3, p62, and ATF4) decreased, apoptosis increased (TUNEL, pH3/Ki-76), and the cell cycle regulator pCDC2 was inhibited. In conclusion, we here showed an anti-tumor effect of Vildagliptin via downregulation of autophagy resulting in increased apoptosis and modulation of the cell cycle. We therefore propose Vildagliptin for the evaluation as a new therapeutic approach for the treatment of colorectal cancer lung metastases.

Available only for authorised users

Gassmann P, Kang ML, Mees ST, Haier J (2010) In vivo tumor cell adhesion in the pulmonary microvasculature is exclusively mediated by tumor cell–endothelial cell interaction. BMC Cancer 10:177CrossRefPubMedCentralPubMed

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403CrossRefPubMed

Kim HK, Cho JH, Lee HY, Lee J, Kim J (2014) Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times? World J Gastroenterol 20:6133–6145CrossRefPubMedCentralPubMed

Abbott CA, Baker E, Sutherland GR, McCaughan GW (1994) Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 40:331–338CrossRefPubMed

Matheeussen V, Jungraithmayr W, De Meester I (2012) Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol Ther 136:267–282CrossRefPubMed

Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH (2008) The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 13:1634–1645CrossRefPubMed

Lambeir AM, Durinx C, Scharpe S, De Meester I (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209–294CrossRefPubMed

Deacon CF (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13:7–18CrossRefPubMed

Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH (2009) CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. Br J Cancer 101:983–991CrossRefPubMedCentralPubMed

10.

Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, Morimoto C (2012) CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res 18:1447–1456CrossRefPubMed

11.

Arwert EN, Mentink RA, Driskell RR, Hoste E, Goldie SJ, Quist S, Watt FM (2012) Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation. Oncogene 31:992–1000CrossRefPubMed

12.

Larrinaga G, Blanco L, Sanz B, Perez I, Gil J, Unda M, Andres L, Casis L, Lopez JI (2012) The impact of peptidase activity on clear cell renal cell carcinoma survival. Am J Physiol Renal Physiol 303:F1584–F1591CrossRefPubMed

13.

Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, Tan VP, Yau TC, Poon RT, Wong BC (2010) A subpopulation of CD26 + cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6:603–615CrossRefPubMed

14.

Dimitrova M, Ivanov I, Todorova R, Stefanova N, Moskova-Doumanova V, Topouzova-Hristova T, Saynova V, Stephanova E (2012) Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumor human lung cells. Tissue Cell 44:74–79CrossRefPubMed

15.

Wesley UV, Tiwari S, Houghton AN (2004) Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 109:855–866CrossRefPubMed

16.

Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, Dang NH, Morimoto C (2007) Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 13:4191–4200CrossRefPubMed

17.

Yamada K, Hayashi M, Madokoro H, Nishida H, Du W, Ohnuma K, Sakamoto M, Morimoto C, Yamada T (2013) Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. PLoS One 8:e62304CrossRefPubMedCentralPubMed

18.

Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH (2001) In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30 + anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 7:2031–2040PubMed

19.

Femia AP, Raimondi L, Maglieri G, Lodovici M, Mannucci E, Caderni G (2013) Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int J Cancer 133:2498–2503CrossRefPubMed

20.

Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Graf R, Clavien PA (2008) Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res 68:5152–5158CrossRefPubMed

21.

Soll C, Jang JH, Riener MO, Moritz W, Wild PJ, Graf R, Clavien PA (2010) Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 51:1244–1254CrossRefPubMed

22.

Lehmann K, Rickenbacher A, Jang JH, Oberkofler CE, Vonlanthen R, von Boehmer L, Humar B, Graf R, Gertsch P, Clavien PA (2012) New insight into hyperthermic intraperitoneal chemotherapy: induction of oxidative stress dramatically enhanced tumor killing in in vitro and in vivo models. Ann Surg 256:730–737; discussion 737–738

23.

Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W (2012) CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg 41:1166–1173CrossRefPubMed

24.

Ponz-Sarvise M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II, Garcia-Franco CE, Garcia-Foncillas J, Montuenga LM, Calvo A, Gil-Bazo I (2011) Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. Clin Cancer Res 17:4155–4166CrossRefPubMed

25.

Cheong H, Lu C, Lindsten T, Thompson CB (2012) Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol 30:671–678CrossRefPubMed

26.

Eng CH, Abraham RT (2011) The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming. Oncogene 30:4687–4696CrossRefPubMed

27.

Cheng HC, Abdel-Ghany M, Elble RC, Pauli BU (1998) Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem 273:24207–24215CrossRefPubMed

28.

Shingu K, Helfritz A, Zielinska-Skowronek M, Meyer-Olson D, Jacobs R, Schmidt RE, Mentlein R, Pabst R, von Horsten S (2003) CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26. Cancer Immunol Immunother 52:546–554CrossRefPubMed

29.

Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112:1809–1820CrossRefPubMedCentralPubMed

30.

Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–734CrossRefPubMed

31.

Xia Y, Lei Q, Zhu Y, Ye T, Wang N, Li G, Shi X, Liu Y, Shao B, Yin T, Zhao L, Wu W, Song X, Xiong Y, Wei Y, Yu L (2014) SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo. Cancer Lett 355:297–309CrossRefPubMed

32.

Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M (2008) (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325:175–182CrossRefPubMed

33.

Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE (2008) Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 10:1057–1061CrossRefPubMed

34.

Spagnuolo PA, Hurren R, Gronda M, MacLean N, Datti A, Basheer A, Lin FH, Wang X, Wrana J, Schimmer AD (2013) Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity. Leukemia 27:1236–1244CrossRefPubMed

35.

He YL, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, Ligueros-Saylan M, Foley JE (2007) Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 47:633–641CrossRefPubMed

Title: Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice
Authors: Jae-Hwi Jang
Lesley Baerts
Yannick Waumans
Ingrid De Meester
Yoshito Yamada
Perparim Limani
Ignacio Gil-Bazo
Walter Weder
Wolfgang Jungraithmayr
Publication date: 01-10-2015
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 7/2015
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-015-9736-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2015

Cellular fibronectin 1 promotes VEGF-C expression, lymphangiogenesis and lymph node metastasis associated with human oral squamous cell carcinoma

Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin

Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA

Expression array analysis of the hepatocyte growth factor invasive program

Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer